Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 8.3% – Should You Sell?

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s share price dropped 8.3% on Wednesday . The stock traded as low as $2.60 and last traded at $2.65. Approximately 99,181 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 1,826,522 shares. The stock had previously closed at $2.89.

Analysts Set New Price Targets

INDP has been the subject of a number of research reports. Wall Street Zen lowered shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Performance

The firm has a market capitalization of $5.57 million, a price-to-earnings ratio of -0.08 and a beta of 0.98. The business’s 50 day moving average is $2.51 and its 200-day moving average is $4.66.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.98) EPS for the quarter, topping the consensus estimate of ($4.17) by $1.19. Equities research analysts forecast that Indaptus Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is currently owned by institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.